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ABSTRACT
Small interfering RNA (siRNA) has excellent phar-
macological features and is expected to be used
for therapeutic drug development. To this end, how-
ever, new RNA technology needs to be established
so that extremely small amounts (less than 1pmol)
of siRNA can be detected in organs of experimental
animals and in human blood to facilitate pharmaco-
kinetics studies. An important feature is that this
new technology is not dependent on radioisotopes
and can detect siRNA molecules identical to those
used for drug development in preclinical tests
with experimental animals or in clinical tests with
humans. We report a convenient method that can
detect small amounts of siRNA. The method uses
high-power confocal microscopic analysis of fluo-
rescence polarization in DNA probes that are
bound to one of the strands of siRNA and directly
quantitates the copy number of siRNA molecule
after extraction from specimens. A pharmacokinetic
study to examine the blood retention time of siRNA/
cationic liposomes in mice showed that this
straightforward method is consistent with the
other reverse transcriptase polymerase chain reac-
tion amplification-based method. We believe that
the entire process is simple and applicable for a
high-throughput analysis, which provides excellent
technical support for fundamental research on RNA
interference and development of siRNA drugs.
INTRODUCTION
RNA interference (RNAi) is induced by incorporating
double-stranded small interfering RNA (siRNA) of
21–25 nucleotides into the RNA-induced silencing com-
plex that directs the cleavage of the complementary
target mRNA in the cytoplasm (1). RNAi is a highly
sequence-speciﬁc post-transcriptional gene silencing
event that permits degradation of speciﬁc mRNAs and
thus has been used broadly as an excellent procedure for
cellular gene knockout experiments. This excellent biolog-
ical activity of siRNA has also been tested for therapeutic
drugs. siRNA as a drug promises several advantages over
traditional drugs, oﬀering new types of medicines that
have a very high target selectivity and that are eﬀective
at a low dose (nanomolar or subnanomolar concentra-
tions) with low toxicity due to metabolism to natural
nucleotide components (2–4).
Development of siRNA therapeutics, however, has been
hampered by several issues, including poor intracellular
uptake due to the intrinsic negatively charged  13K
molecular weight structure and limited stability in circu-
lating blood. Another key issue has been the absence of a
convenient method to detect small amounts of siRNA in
its natural form to monitor the pharmacokinetics in cells,
circulating blood and organs. A small amount of siRNA
present in the circulating blood is diﬃcult to quantitate
by conventional column chromatographic procedures due
to limited ultraviolet absorption of the administered
siRNA.
Previously, as a pioneering eﬀort, Sato et al. (5,6)
measured the retention time of siRNA stabilized with
cationic polymers in the circulating blood of mice by
using ﬂuorescence-labeled siRNA and polyacrylamide
gel electrophoresis that allowed simultaneous isolation
and visualization of siRNA. However, this method
has several drawbacks: (i) it is unable to measure non-
ﬂuorescent (or non-radioactive) siRNA, such as unmodi-
ﬁed siRNA in its natural form, (ii) it is technically tedious
to run the gel electrophoresis, (iii) it fails to obtain accu-
rate estimates of the amount of siRNA and (iv) it cannot
handle many samples. Futami et al. (7) invented a new
method to amplify siRNA of 21-mers containing 30-TdT
to DNA after 30-terminal dG-tailing by using terminal
deoxytransferase and reverse transcriptase polymerase
chain reaction (RT–PCR) with a primer containing
oligo-dC, referred to as the TdT/RT–PCR method.
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In this article, we describe a new method to estimate
small amounts of siRNA that does not use RT-PCR
but depends on the theory of ﬂuorescence correlation
spectroscopy (FCS) described by Edman (8). A single-
molecule ﬂuorescence detection system (MF20, Olympus
Corporation, Tokyo, Japan), equipped with a confocal
microscope and ﬂuorescence spectroscopy, detects small
ﬂuorescence signal changes coming from a DNA probe
hybridized with target siRNA molecules in a very small
confocal volume of a light path chamber (1.5 fL). Samples
at several nanomolar concentrations contain a few mole-
cules of siRNA in such a small volume, so that signals
directly reﬂect the concentration and the diﬀusion time
of ﬂuorescence molecules. Usually, the ﬂuorescence-
labeled DNA probe that increases the apparent molecular
weight by 5–8-fold after hybridizing with speciﬁc target
nucleic acids shows a reduced Brownian motion, resulting
in an increased diﬀusion time in the confocal volume and
a ﬂickering of ﬂuorescence that are used to estimate the
degree of hybridization of the DNA probe. The number
of ﬂuorescence signal changes is expressed by the ‘count-
rate’ that indicates the number of photons per second
detected in the light path chamber being measured (9).
Accordingly, in this study, we tested ﬂuorescence intensity
distribution analysis polarization (FIDA–PO) developed
by Palo et al. (10,11) that overcomes the technical limita-
tion of FCS that measures mainly ﬂuorescence intensity
changes due to the altered molecular mass and diﬀusion
time of the ﬂuorescent ligand. FIDA–PO has been used
before for protein kinase assays, diagnosis of single-
nucleotide polymorphism (12,13) and for studying the sta-
bility of ﬂuorescence-labeled siRNA bound to cationic
polymers in blood (5).
We found that FIDA–PO can be used to estimate the
amounts of ﬂuorescence-labeled DNA probes in DNA/
RNA heteroduplexes formed by hybridization with one
of the strands of siRNA, even though the apparent molec-
ular size of DNA probe increases by only 2-fold after
annealing to siRNA. Here, we report that the FIDA–PO
system combined with single-molecule ﬂuorescence detec-
tion is convenient for quantitative and high-throughput
analysis of many siRNA samples extracted from cells
and blood of administered animals. We believe that this
FIDA–PO method facilitates pharmacokinetics studies
on siRNA and drug-delivery studies, expediting the devel-
opment of siRNA medicines.
MATERIALS AND METHODS
siRNAs and fluorescence-labeled DNA probes
All siRNAs consisted of 19-bp RNA duplexes and two
overhanging 30-dTdT at the 30 termini. GL3–siRNA repre-
sents the sequence of part of the ﬁreﬂy luciferase gene
(GL3, Promega) that is not present in human cells and
was used in this study. It contains a duplex of strands
containing sequences 50-CUUACGCUGAGUACUUCG
AdTdT-30 (sense strand) and 50-UCGAAGUACUCAGC
GUAAGdTdT-30 (antisense strand). Other siRNA
sequences used in this study were NS (nonspeciﬁc)-
siRNA that contained sequences 50-UUCUCCGAACG
UGUCACGUdTdT-30 and 50-ACGUGACACGUUCG
GAGAAdTdT-30 that were conﬁrmed not to interact
with any known mRNA sequence by homology search
by using the Smith and Waterman method, and
RecQL1–siRNA that contained sequences 50-GUUCAG
ACCACUUCAGCUUdTdT-30 (sense strand correspond-
ing to the position 273–291 in RecQL1 mRNA) and 50-AA
GCUGAAGUGGUCUGAACdTdT-30 (antisense strand)
(14). The Tm values for these siRNAs were 53.98C
for GL3–siRNA (GC content 47.4%), 56.08C for NS–
siRNA (GC content 52.6%) and 53.98C for RecQL1
(GC content 47.3%). DNA probes that detect GL3–
siRNA, NS–siRNA or RecQL1–siRNA consisted of
21-mer oligonucleotides that were chemically synthesized
and were puriﬁed to over 95% homogeneity by using
reverse phase column chromatography, and they
were labeled at the 50 end by TAMRA (tetra methyl-
rhodamine) (Sigma–Aldrich Japan, Tokyo, Japan) or
Alexa Fluor 647 (Japan Bio Services Co., Ltd, Saitama,
Japan).
Cells and siRNA transfection
A549 (human lung carcinoma) cells obtained from ATCC
(Manassas, VA, USA) were cultured at 378C in a humidi-
ﬁed chamber supplemented with 5% CO2. The culture
medium and method were as described in the supplier’s
instructions. For transfection with siRNA, the cells were
plated, proliferated by culturing for 24h and then were
incubated for 8h with 40nM siRNA duplex using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
The cells were then cultured in fresh medium under the
conditions described before (14).
Systemic administration ofsiRNA/liposome complex to
mice and measurement of siRNA retained inblood
Animal procedures were approved by the committee
for the institutional care and use of animals at
GeneCare Research Institute Co. Ltd in accordance with
the guidelines for animal experimentation prepared by
the Japanese Association for Laboratory Animal
Science. RecQL1–siRNA/LIC-101 complex (50mg
siRNA/mouse) was injected intravenously into ICR mice
(n=3) purchased from CLEA Japan (Tokyo, Japan). The
LIC-101 liposome consists of 2-O-(2-diethylaminoethyl)-
carbamoyl-1, 3-O-dioleylglycerol and egg phosphatidyl-
choline. Mouse blood (30ml) was taken from the tail
vein at 0.5, 1, 3, 6, 12 and 24h after administration of
the siRNA/liposome complex. Half of the blood (15ml)
was diluted 10-fold by mixing with 135ml of phosphate-
buﬀered saline (PBS) containing 50mM ethylenediamine
tetraacetate (EDTA), and the siRNA was extracted
as described in the ‘Extraction of siRNA’ section
below. The formulation process of the RecQL1–siRNA/
LIC101 complex was done in the laboratory of Nippon
Shinyaku Co., Ltd (Kyoto, Japan) as reported by Yano
et al. (15).
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The siRNAs transfected in vitro to cells were extracted
from cells after 6, 12, 24, 48, 72 and 96h as we had
described earlier (14). siRNAs administered in vivo to
mice by intravenous injection were extracted from blood
after 30min and at 1, 3, 6, 12 and 24h as we described
earlier (7). siRNAs delivered to mouse organs were
extracted, in a form of total RNA, from excised and
ground organs 30min after the intravenous injection of
RecQL1–siRNA/LIC101 complex. Extraction was done
by using phenol and chloroform, and the extracted total
RNA was puriﬁed by using the miRNeasy Mini Kit
(Qiagen, Hilden, Germany) following the instructions of
the manufacturer. As the internal control, GL3–siRNA
(50pmol) was added to the grounded organ to standardize
the recovery of RNA during the extraction process.
Detection ofsiRNA by FIDA–PO system
Fluorescence changes in the labeled DNA probe were
monitored by using FIDA–PO before and after hybridiza-
tion with siRNA, similar to its use to detect other biolog-
ical materials (5,9,12,13). A standard curve was made for
each labeled DNA probe by using a 2nM DNA probe at
varying concentrations (0–200nM) of siRNA in 30ml
of hybridization reaction mixture consisting of 20mM
Tris–HCL (pH 7.5), 1mM EDTA and 100mM NaCl.
After hybridization under the conditions described
below, the ﬂuorescence changes in the DNA probe were
measured and plotted. The non-linear standard curve
obtained from the measurements of increasing concentra-
tions of siRNA was smoothened by ﬁtting equation
y=bottom+(top – bottom) {A0+S+Kd   [(A0+
S+Kd)^2–4 A0 S]^(1/2)}/(2 A0) (where bottom
represents the value obtained with 0nM siRNA, top
represents the value with 200nM siRNA, A0 is the con-
centration of the DNA probe, S is the concentration of
siRNA and Kd is the dissociation constant between the
DNA probe and siRNA antisense chain). The Kd value
measured in the hybridization reaction mixture containing
100mM NaCl was 5.27 1.48nM, and it was used for the
standard curve for FIDA–PO analysis.
RNA fractions, extracted from cultured cells or blood,
were puriﬁed by using the column in the miRNeasy Mini
Kit. The RNA solution (5–6ml) was diluted to a total of
30ml by adding 20mM Tris–HCl (pH 7.5) buﬀer contain-
ing 1mM EDTA and 100mM NaCl. The single-stranded
DNA probe was mixed in this solution at concentration
2nM, and hybridization was done in Eppendorf tubes by
incubation at the following temperatures: the annealing
condition changed at interval times of 50s from 958C
for 5min to 908C for 5min, 808C for 10min, 708C for
10min, 608C for 10min, 508C for 10min, 408C for
10min, 308C for 10min and ﬁnally to room temperature
(208C). After hybridization of the ﬂuorescent DNA probe
with the complimentary strand of siRNA, each sample
(30ml) was monitored ﬁve times by FIDA–PO analysis
by using an MF20 apparatus (Olympus Corporation,
Japan) equipped with a confocal microscope and a laser.
Every measurement of the polarized ﬂuorescent light
yielded from the 100mW of 543nm laser light irradiation
was done automatically for 15s at each monitoring (a
total of 75s per sample). The increased diﬀusion time
(microseconds: represented as K1) of the annealed labeled
DNA probe/siRNA complex, as well as the change in the
intensity of ﬂuorescence polarization (FP: represented as
mP), were measured and computed automatically by using
softwares installed in MF20. All measurements were done
at room temperature around 208C.
Quantitative analysis ofsiRNA by theTdT/RT–PCR
method
The overhanging 30 terminal dTdT of siRNA can be eﬃ-
ciently 30-oligo–dG-tailed by incubation with terminal
deoxynucleotidyl transferase (EC2.7.7.31) and dGTP.
The oligo dG-tailed siRNA sequences are ﬁrst converted
to cDNA by oligo–dC-containing primer and reverse tran-
scriptase, and then the resulting oligo–dC-containing
cDNAs are ampliﬁed by PCR. Quantitative PCR can be
done with these cDNA templates. This method works well
for 30-dTdT-containing siRNA. The method was invented
by Futami and Furuichi (16) and was used previously to
determine the retention time of RecQL1–siRNA in the
circulating blood of mice that were intravenously injected
with the RecQL1–siRNA/LIC-101 complex (7).
RESULTS
Detectionof thesiRNA/DNA probeheteroduplex by FP
Various concentrations of GL3–siRNA were heat-
denatured, were hybridized with a ﬂuorescent TAMRA-
labeled DNA probe, and the resulting siRNA/DNA probe
heteroduplex underwent single-molecule ﬂuorescence
detection by using an MF20 apparatus to test if ﬂuores-
cence emission from the labeled DNA probe may be
aﬀected after heteroduplex formation with siRNA
(Figure 1). The MF20 apparatus has multiple functions,
such as FCS, FIDA (ﬂuorescence intensity distribution
analysis) and FIDA–PO, which enable monitoring of the
activity of the ﬂuorescence-labeled molecules from various
aspects. We found that FIDA–PO can monitor FP in
accordance with molecular change in a DNA probe
from single-stranded DNA to a base-paired DNA/RNA
heteroduplex.
The labeled DNA probe at concentrations 0.5nM, 2nM
and 10nM was tested to detect GL3–siRNA of varying
concentrations from 0.001 to 100nM (Figure 2A). To our
surprise, the FP of the DNA probe increased markedly
after binding to siRNA (21-mers) even when the molecular
weight shift of the DNA probe (21-mers) before and after
heteroduplex formation was assumed to be only 2-fold.
Figure 2A shows that the relative FP change (represented
as mP) of the DNA probe increased dose-dependently
as the siRNA concentration increased. The degree of
FP change did not diﬀer markedly between the three
concentrations of the DNA probe, sharing a similar sig-
moidal proﬁle of FP change against increasing siRNA
concentrations.
These results suggested that the FP change of labeled
DNA probe in a heteroduplex can be used to detect
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under the appropriate DNA probe concentration.
The labeled DNA probe of 2nM, however, seemed to be
most appropriate, because it showed a wider coverage in
detection of siRNA (approximately from 0.5 to 50nM)
with a linear dose dependency. The data obtained with
the 2nM DNA probe was smoothened to serve as the
standard curve by ﬁtting a program (Figure 2A, inset),
and the later experiments were done with this 2nM
DNA probe condition. When these experimental data
were analyzed from the aspect of diﬀusion time of
annealed DNA probe by using FCS, the diﬀusion time
increased as if the Brownian movement of the
Fluorescence-labeled oligo DNA
ss-siRNA
Annealing
DNA-RNA
Heteroduplex
ds-siRNA
Heat denature
Figure 1. Schematic representation of siRNA detection by DNA probe/
siRNA heteroduplex formation and ﬂuorescence polarization. A DNA
probe labeled at the 50 or 30 terminus with a ﬂuorescent ligand, which is
illustrated by a bar having diagonal lines and a jagged blob, binds by
annealing to the complimentary single-stranded siRNA. The ﬂuores-
cence polarization changes generated by the DNA–RNA heteroduplex
formation were detected by using a confocal microscope without
removal of the free DNA probe.
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Figure 2. Quantitation of siRNA by FIDA–PO of the DNA probe/siRNA heteroduplex. Various concentrations of GL3–siRNA (0.001–100nM)
were hybridized with 0.5, 2 and 10nM DNA probe (21-mer) that consisted of a 21-mer GL3–siRNA-speciﬁc sequence and a 50 TAMRA-labeled
terminus. Hybridization was done as described in the ‘Materials and Methods’ section. The reaction mixtures were placed in an automated MF20
sample feeder and underwent analysis with FCS, FIDA and FIDA–PO. Each sample was analyzed ﬁve times for 15s, a total of 75s and the averaged
values were recorded. Fluorescent light (or polarization) emitted by irradiation of 100mW laser light (543nm) was measured and translated as
diﬀusion time (K1) or as polarized ﬂuorescent intensity (mP). (A) FIDA–PO analysis, (B) FCS analysis and (C) FIDA analysis. Closed triangle:
0.5nM, closed square: 2nM, closed diamond: 10nM. Error bars show standard deviation (SD).
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apparent molecular weight of the complex increased as
the concentration of siRNA increased (Figure 2B). The
results with FCS showed that the diﬀusion time of the
GL3–DNA probe increased dose dependently, but only
slightly from 330ms (microseconds) to about 400ms
(Figure 2B). We noted that these diﬀusion time changes
were distinct, but they were not large enough to be used to
quantitate siRNA.
In the FIDA assay that measured the ﬂuorescence
intensity (as shown by Q [kHz]) of individual DNA
probes, the intensity of ﬂuorescence from the DNA
probe also increased dose dependently, but only margin-
ally at about 5–10 Q [kHz] increments under all DNA
probe concentrations tested (Figure 2C). The increments
were not large enough to be used to estimate siRNA con-
centration. In the FIDA assay, the intensity of ﬂuores-
cence of each DNA probe molecule tended to be
inﬂuenced by the initial concentration of the DNA
probe, i.e. the higher the concentration of DNA probe,
the lower was the intensity of ﬂuorescence emitted from
each molecule of DNA probe (Figure 2C).
DNA probe sequence-specific detection of siRNA by
FIDA–PO
To test if the FP change in DNA probe is sequence-speciﬁc
and is also hybridization-dependent, we tested the eﬀect of
siRNA sequences other than GL3–siRNA. NS–siRNA
containing an arbitrary sequence and a ﬂuorescence-
labeled DNA probe that can detect NS–siRNA was pre-
pared, and it was used for cross-hybridization experiments
with GL3–siRNA and its cognate DNA probe. The dose
dependency was also examined for a wide range of siRNA
concentrations from 0.01 to 200nM with 2nM of ﬂuores-
cence-labeled DNA probes (Figure 3). The GL3–DNA
probe detected GL3–siRNAs at a successive range of con-
centrations from 0.1 to 100nM, but it did not interact with
non-matching NS–siRNA, even at high concentration
200nM (Figure 3A). The FP of the the NS–DNA probe
was unaﬀected vice versa by non-matching 1nM and
200nM GL3–siRNA (Figure 3B). These results indicate
that FIDA–PO analysis with a 21-mer DNA probe can
measure siRNA of concentrations from as low as less than
0.1–50nM sequence-speciﬁcally.
Detectionof siRNAs in cells
We tested FIDA–PO analysis to monitor the metabolism
of siRNA transfected to cells under cultivation. We used
RecQL1–siRNA that can silence endogenous RecQL1
helicase mRNAs existing abundantly in growing cancer
cells to understand the fate of siRNA functioning in
cells (17). RecQL1–siRNA in a complex with lipofecta-
mine was transfected into human lung cancer A549 cells
at concentration 40nM (containing 40pmol siRNA in
1ml of medium) by incubation at 378C for 8h. A549
cells were then removed from the Petri dish, were
washed with PBS and then the total cellular RNA was
extracted at times 6, 12, 24, 48, 72 and 96h and the
amounts of RecQL1–siRNA were measured by FIDA–
PO analysis by using the RecQL1-speciﬁc DNA probe
as described in the ‘Materials and Methods’ section. The
RecQL1–siRNA-speciﬁc DNA probe consisting of a sense
sequence does not react with cellular nucleic acids such as
tRNA, ribosomal RNA, endogenous microRNAs and
RecQL1 mRNA. The A549 cell RNA extract was moni-
tored separately by a DNA probe complimentary to
non-speciﬁc siRNA as a negative control. As an internal
control, NS-siRNA (20pmol) was added to the cell lysate
to monitor the recovery of siRNA during the extrac-
tion process. Figure 4 shows the time course of
80
100
120
140
160
180
200
220
2
0
0
1
0
0
5
0
2
0
1
0
5
2
1
0
.
5
0
.
2
0
.
1
0
.
0
5
0
.
0
2
0
.
0
1
0
2
0
0
1
m
P
100
120
140
160
180
200
220
2
0
0
1
0
0
5
0
2
0
1
0
5
2
1
0
.
5
0
.
2
0
.
1
0
.
0
5
0
.
0
2
0
.
0
1
0
2
0
0
1
m
P
NS siRNA GL3 siRNA
B A
GL3 siRNA NS siRNA
Figure 3. Sequence-speciﬁc quantitation of siRNA by FIDA–PO. (A) GL3–siRNAs of increasing concentrations from 0 to 200nM underwent
FIDA–PO analysis with a 2nM GL3–DNA probe. NS–siRNAs (1nM, 200nM) were tested as negative controls. (B) NS–siRNAs of increasing
concentrations from 0.01nM to 200nM underwent FIDA–PO analysis with a 2nM NS–DNA probe. GL3–siRNAs (1nM, 200nM) were tested as
negative controls. Error bars show the SD.
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RecQL1–siRNA detected by the speciﬁc DNA probe
decreased gradually as A549 cell culturing proceeded,
giving rise to a half-life of about 96h. Over 90% of
RecQL1 mRNA was silenced in 24h by the RNAi reac-
tion, as we determined by using RT–PCR (7). In contrast,
the non-speciﬁc DNA probe that was used in the negative
control experiment showed no sign of FIDA–PO, justify-
ing the speciﬁc interaction of the RecQL1–DNA probe
with the transfected RecQL1–siRNA.
Quantitationof siRNAs in circulating blood
We used FIDA–PO analysis to monitor the retention
of intravenously injected siRNA in circulating blood of
mice. The RecQL1–siRNA/LIC-101 complex (50mg
siRNA/mouse) was administered to mice, and their
blood was taken from the tail vein at 0.5, 1, 3, 6, 12 and
24h after administration. The blood was diluted 10-fold
by extraction buﬀer, and RNA was extracted as described
in the ‘Materials and Methods’ section. RNA was dis-
solved in a small volume of buﬀer (30ml), and aliquots
were analyzed for the amount of siRNA by using the
FIDA–PO system. Figure 5A shows the time course of
the change in concentration of RecQL1–siRNA in the
circulating mouse blood. The data show that RecQL1–
siRNA in the complex with LIC-101 liposome disap-
peared from circulating blood quickly with an initial
half retention time of <0.5h. To ﬁnd if the kinetics data
obtained by this FIDA–PO system is consistent with the
data obtained by other methods, we compared the data
with data obtained by the PCR-mediated, ampliﬁcation-
based method previously described (7,16). The method of
this study is referred to as the TdT/RT-PCR method that
can estimate the amount of siRNA having a 30-TdT
sequence. The results obtained from these two indepen-
dent methods were almost identical at 0.5 and 3h. In
this study, the RecQL1–siRNA/LIC101 complex was
delivered preferentially and quickly to the liver after
intravenous administration into the tail vein of mice
because LIC101 is a liver-prone cationic liposome (7,15).
The pharmacokinetics of RecQL1–siRNA formulated
with LIC-101 liposome are distinct, because most
RecQL1–siRNA was delivered to the liver within 5min
after administration, whereas most of the other remained
for about 3h in circulating blood and then disappeared
gradually within 6h. This kinetic data associated with
the liver-prone siRNA/liposome complex was conﬁrmed
by the FIDA–PO system and TdT/RT-PCR method.
Thus, the pharmacokinetic study of siRNA drug at nano-
molar levels can be achieved by FIDA–PO analysis with-
out amplifying siRNA by RT–PCR or by preparing and
handling cumbersome radioactive siRNA. This straight-
forward method that detects siRNA molecules by using a
confocal microscope with a single-molecule ﬂuorescence
detection system can avoid bias of predicting the initial
amount of siRNA after ampliﬁcation by RT–PCR.
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Figure 4. Detection of siRNA in cells by FIDA–PO analysis. RecQL1–
siRNA was transfected to A549 human lung carcinoma cells (1.5 10
4)
with Lipofectamine as described in the ‘Materials and Methods’ sec-
tion. At 8h after transfection, cells were washed and cultured in fresh
medium. siRNA was extracted from cells at the indicated time after
transfection. Extraction of RNA was done as described in the
‘Materials and Methods’ section, and the amount of RecQL1–siRNA
present in the extracts was determined with a 2nM RecQL1–DNA
probe. Error bars show the SD.
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Figure 5. FIDA–PO analysis for the pharmacokinetics of intravenously
injected siRNA in mouse blood and siRNA distribution in mouse
organs. RecQL1–siRNA (50mg) was injected intravenously into mice
(n=3) in the form of a siRNA/liposome complex or a RecQL1–
siRNA/LIC101 complex in 10% maltose solution. (A)
Pharmacokinetics in mouse blood; mouse blood (30ml) was extracted
from the tail vein at 30 and 60min and at 3, 6, 12 and 24h after
administration, and an RNA fraction was extracted as described in
the ‘Materials and Methods’ section. The amount of RecQL1–siRNA
was determined by using the FIDA–PO system and was represented as
siRNA weight (mg) per whole blood (2ml) of mouse. The results were
compared with results using the TdT/RT–PCR method (7,16). White
columns show data obtained by FIDA–PO analysis, and hatched col-
umns show data by using the TdT/RT–PCR method. Error bars show
the SD. (B) Determination of siRNA distribution in mouse organs;
after 30min, an RNA fraction was extracted from excised mouse
organs as described in the ‘Materials and Methods’ section. The
amount of siRNA was determined by using the FIDA–PO system
and was represented as siRNA weight (mg) per whole tissue of
mouse. White columns show data obtained by FIDA–PO analysis,
and hatched columns show data by using the TdT/RT-PCR method.
Error bars show the SD.
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We tested the FIDA–PO procedure to determine the dis-
tribution of siRNA in mouse organs after systemic admin-
istration by intravenous injection. The RecQL1–siRNA/
LIC-101 complex (50mg siRNA/mouse) was used for this
experiment, and the RNA fractions were extracted from
the liver and kidney at 0.5h after administrations. Three
mice were used in this experiment, and one sample from
each mouse underwent FIDA–PO analysis independently
after appropriate dilutions. The data indicate that a sub-
stantial portion of the administered RecQL1–siRNA
was delivered to the liver, consistent with the liver-prone
property of the LIC-101 carrier (Figure 5B). Only a small
amount of RecQL1–siRNA was found in the kidney.
These data are also consistent with previous conclusions
obtained by using the TdT/RT–PCR procedure.
Noteworthy is that measurements of siRNA by FIDA–
PO analysis are consistent and reproducible.
DISCUSSION
RNAi technology is now indispensable for basic research,
and siRNA-mediated screening is quite popular in phar-
maceutical industries to ﬁnd target genes to discover drugs
that manage disorders in various disease ﬁelds. Eﬀorts to
use the siRNA molecule itself for therapeutic drugs have
also been increasing in various ﬁelds of human diseases.
The development of siRNA drugs has been realized after
establishing the basis of the siRNA function in silencing
speciﬁc mRNA, and after solving several problems asso-
ciated with the therapeutic use of siRNA, such as an oﬀ-
target eﬀect caused by less strict sequence matching (18),
an interferon-inducing eﬀect caused by a high dose of
siRNA (19), TOL3 receptor interacting RNA molecules
(20) and setting up large-scale chemical synthesis of pure
siRNA (21).
Many examples exist in research that show anti-cancer
activities of siRNA in various animal models. For exam-
ple, siRNAs that can silence the expression of vasoactive
epidermal growth factor required for angiogenesis of
malignant cancers prohibit the growth of prostate cancer
cells, resulting in regression of cancers (22). In mouse
models of metastatic lung cancer, siRNAs that can sup-
press the expression of Bcl-2 that represses cancer cell
apoptosis are eﬃcacious (15). Acute depression of PLK1
(Polo-like kinase 1) that participates in cell-cycle progres-
sion by siRNA results in marked inhibition of growth of
bladder cancers (23). However, these ﬁndings have not so
far been substantiated by accurate pharmacokinetic data
of siRNA concentrations present in cancer cells or blood.
Previously, we showed that RecQL1–siRNA, which
silences the expression of RecQL1 DNA helicase partici-
pating in DNA repair during cell-cycle progression, selec-
tively kills a wide spectrum of cancer cells without
aﬀecting normal cells (14). During our study, we noted
that siRNA drug development needs reliable methods
that can monitor small amounts of siRNA distributed at
low concentrations in cells, blood and targeted organs.
Imperative is that such methods can monitor the same
siRNA species to be used for a therapeutic purpose and do
not monitor the labeled siRNA prepared specially for a
tracking purpose. Using highly radioactive siRNA for
human use is not practical. Chemically modiﬁed siRNA,
such as siRNA labeled with a multi-ring ﬂuorescein mole-
cule, does not necessarily represent the true pharmacolog-
ical nature of siRNA. Rhodamin dye tends to be
incorporated preferentially into cancer cells instead of
into normal cells by binding to speciﬁc surface proteins
or through the active channel function of cancer cells (24).
In this context, the FIDA–PO system provides convincing
measurements of siRNA based on straightforward meth-
ods, including only hybridization with a DNA probe and
confocal single-molecule ﬂuorescence detection, and thus
it can directly quantitate the same siRNA preparations
administered in preclinical or clinical studies without
having complicated processes of ampliﬁcation that are
laborious and are often associated with error and
inaccuracy.
From the sensitivity viewpoint, the FIDA–PO system
can easily detect 0.5–50 nanomolar concentrations of
siRNA existing in 30ml of reaction mixture (Figures 2
and 5). Because confocal volumes needed for measure-
ment are only 1 fL, and the hybridization volume can be
lowered to a few microliters, siRNA of less than 100fmol
(about 1ng of siRNA of molecular weight 13kDa) can be
quantitated. From the viewpoint of reaction time, FIDA–
PO permits a rapid determination of about less than 1min
for each sample by using the fully automated MF20
instrument. The total time, including of the hybridization
reaction, is about 90min and the whole process is simple;
and no washing-oﬀ or removal of free DNA probe is nec-
essary after annealing to the complimentary strand of
siRNA. The method is reproducible and is resistant to
contamination of high molecular weight RNAs, such as
transfer RNAs and ribosomal RNAs.
In this study, we initially used a TAMRA-labeled DNA
probe that is activated by He–Ne laser (543nm) and emits
ﬂuorescence light. To investigate if the ﬂuorescence ligand
inﬂuences the quantitation of siRNA, we tested ﬂuores-
cence ligand molecules other than TAMRA and found
that quantitative detection of siRNA was possible with
other kinds of ﬂuorescence markers, such as Alexa Fluor
647 that is excited by laser light of wavelength 633nm
(data not shown). These results indicated that FIDA–PO
analysis can achieve simultaneous detection of multiple
siRNA species independently by using DNA probes con-
taining diﬀerent emission wavelengths.
When the RecQL1–siRNA/LIC-101 complex was intra-
venously injected into mice, the results of analyzing its
retention in circulating blood and distribution in organs
by using the FIDA–PO method fall within the similar
ranges of siRNA concentration obtained by using the
independent TdT/RT–PCR method (Figures 4 and 5).
This comparative study indicated that both methods are
compatible and perhaps can complement each other to
assure the conclusion of pharmacokinetic experiments.
Although the precise physico-chemical mechanism(s)
underlying FIDA–PO changes in the DNA probe after
annealing to siRNA remains to be studied, we believe
that the FIDA–PO system will contribute to quantitation
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of siRNA medicines.
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